Literature DB >> 30626509

Special Considerations and Assessment in Patients with Multiple Sclerosis.

Ian B Maitin1, Ernesto Cruz2.   

Abstract

Multiple sclerosis is a progressive autoimmune neurologic disorder that may affect any region of the central nervous system. Spasticity in patients with multiple sclerosis can be debilitating and detrimental to the function and quality of life of patients. Treatment options include oral medications, chemodenervation, physical therapy, and modalities. Cannabinoids in the form of a delta-9-tetrahydrocannabinol/cannabidiol oro-mucosal spray has been shown to be effective in addressing spasticity in multiple sclerosis. Successful treatment of spasticity will be integrated, multimodal, and individualized.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Botulinum toxin; Cannabinoids; Multiple sclerosis; Spasticity

Mesh:

Year:  2018        PMID: 30626509     DOI: 10.1016/j.pmr.2018.03.003

Source DB:  PubMed          Journal:  Phys Med Rehabil Clin N Am        ISSN: 1047-9651            Impact factor:   1.784


  4 in total

1.  The co-occurrence of multiple sclerosis and Evans syndrome: A case report.

Authors:  Saeideh Salehizadeh; Abdorreza Naser Moghadasi; Mohammad Ali Sahrain
Journal:  Caspian J Intern Med       Date:  2020-05

Review 2.  Viral infections and their relationship to neurological disorders.

Authors:  Jéssica Wouk; Daniele Zendrini Rechenchoski; Bianca Cerqueira Dias Rodrigues; Elisa Vicente Ribelato; Ligia Carla Faccin-Galhardi
Journal:  Arch Virol       Date:  2021-01-27       Impact factor: 2.574

3.  Dry needling for treating spasticity in multiple sclerosis.

Authors:  María Del Pilar Pérez-Trujillo; Montserrat González-Platas; María Yaiza Pérez-Martín; María Consuelo Revert-Gironés; Javier González-Platas
Journal:  J Phys Ther Sci       Date:  2021-07-01

4.  MS Spasticity: Take Control (STC) for ambulatory adults: protocol for a randomized controlled trial.

Authors:  Cinda L Hugos; Michelle H Cameron
Journal:  BMC Neurol       Date:  2020-10-07       Impact factor: 2.474

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.